Premium
Preventive Effect of Fibroblast Growth Factor and Hepatocyte Growth Factor on Ceramide‐Induced Dysfunction Human Small Intestinal Cells
Author(s) -
Yamaguchi Ryo,
Takami Yoshihiro,
Iida Takuya,
Shimazaki Syuij
Publication year - 2005
Publication title -
wound repair and regeneration
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.847
H-Index - 109
eISSN - 1524-475X
pISSN - 1067-1927
DOI - 10.1111/j.1067-1927.2005.130116h.x
Subject(s) - hepatocyte growth factor , ceramide , apoptosis , basic fibroblast growth factor , growth factor , fibroblast growth factor , cell growth , endocrinology , medicine , cancer research , biology , microbiology and biotechnology , biochemistry , receptor
Purpose: Gastrointestinal (GI) damages associated with multiple organ failure is a fatal complication. The injured function of GI tract causes malnutrition and the bacterial translocation. So the functional recovery of GI tract is quite important for treating such cases. In the present study, we investigated whether basic fibroblast growth factor (bFGF) and hepatocyte growth factor (HGF) could recover the injured functions of cultured intestinal cells. Method: Human small intestinal cells were cultured in a 10% FCS added DMEM. The cellular damages were induced by the treatment with various concentrations of cell permeable C6‐ceramide (0–20 M). Growth factors (10 ng/ml bFGF or 50 ng/ml HGF) were added to the medium simultaneously or 2 days after the beginning of the ceramide treatment. After 4 days of the treatment, cell growth and apoptosis induction were investigated. Result and Conclusion: Ceramide inhibited cell growth and induced apoptosis in a dose‐dependent manner. Both growth factors significantly improved the cell growth and reduced apoptosis. These effects were also observed when the growth factor treatment was delayed 2 days after the ceramide treatment. It was found that bFGF was more significant than HGF on these protective effects. It is suggested that growth factor treatment may be a useful therapeutic option to improve GI tract dysfunction.